Skip to main content
Premium Trial:

Request an Annual Quote

Aptalis Pharma taps NuMedii to Select Candidates for Drug Research


NuMedii said this week that it will use its predictive platform to identify potential therapeutic candidates for gastrointestinal disorders and cystic fibrosis for Aptalis Pharma.

Under the terms of the collaboration, NuMedii will provide proprietary, de-risked drug candidates, while Aptalis will handle the development and commercialization of the treatments it chooses to pursue.

Furthermore, NuMedii will receive an initial upfront payment along with development and commercial milestone payments plus royalties on sales of each product developed under the collaboration, the company said.

NuMedii was spun out of Stanford University last year to commercialize computational methods for identifying new drugs (BI 12/2/2011). The company uses network-based algorithms to analyze disease, pharmacological, and clinical data in order to identify drug-disease connections and biomarkers that are predictive of efficacy.